0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Checkpoint Inhibitors"

Following a topic allows Research and Markets to customize your experience and provide personalized recommendations.
From
EUR$3,545USDGBP
EUR$3,939USDGBP
From
EUR$3,545USDGBP
EUR$3,939USDGBP
From
EUR$3,545USDGBP
EUR$3,939USDGBP
From
EUR$3,545USDGBP
EUR$3,939USDGBP
From
EUR$5,600USDGBP
Bone Cancer Treatment - Global Strategic Business Report - Product Thumbnail Image

Bone Cancer Treatment - Global Strategic Business Report

  • Report
  • March 2025
  • 367 Pages
  • Global
From
EUR$5,600USDGBP
Oncology Clinical Trials - Global Strategic Business Report - Product Thumbnail Image

Oncology Clinical Trials - Global Strategic Business Report

  • Report
  • March 2025
  • 283 Pages
  • Global
From
EUR$5,600USDGBP
Testicular Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Testicular Cancer Drugs - Global Strategic Business Report

  • Report
  • March 2025
  • 269 Pages
  • Global
From
EUR$5,450USDGBP
Esophageal Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Esophageal Cancer Drugs - Global Strategic Business Report

  • Report
  • March 2025
  • 269 Pages
  • Global
From
EUR$5,600USDGBP
MEK Inhibitors - Global Strategic Business Report - Product Thumbnail Image

MEK Inhibitors - Global Strategic Business Report

  • Report
  • March 2025
  • 132 Pages
  • Global
From
EUR$5,600USDGBP
Blood Cancer Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Blood Cancer Therapeutics - Global Strategic Business Report

  • Report
  • March 2025
  • 291 Pages
  • Global
From
EUR$5,600USDGBP
Immuno-Oncology - Global Strategic Business Report - Product Thumbnail Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • March 2025
  • 224 Pages
  • Global
From
EUR$4,950USDGBP
From
EUR$4,950USDGBP
Sarcoma Drugs - Global Strategic Business Report - Product Thumbnail Image

Sarcoma Drugs - Global Strategic Business Report

  • Report
  • March 2025
  • 93 Pages
  • Global
From
EUR$5,600USDGBP
From
EUR$4,950USDGBP
Gynecological Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Gynecological Cancer Drugs - Global Strategic Business Report

  • Report
  • March 2025
  • 193 Pages
  • Global
From
EUR$5,450USDGBP
Cancer Immunotherapy - Global Strategic Business Report - Product Thumbnail Image

Cancer Immunotherapy - Global Strategic Business Report

  • Report
  • March 2025
  • 93 Pages
  • Global
From
EUR$5,600USDGBP
Loading Indicator

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more

This website uses cookies to ensure you get the best experience. Learn more